Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare initiates trials for new fat reduction treatment

Bayer HealthCare initiates trials for new fat reduction treatment

12th January 2011

Bayer HealthCare has commenced two clinical trials of a collaboratively-developed new treatment for the reduction of localised fat under the chin.

In association with partner Kythera Biopharmaceuticals, the company's dermatology business unit Intendis has begun enrolling patients for a pair of phase III studies of ATX-101, a first-in-class injectable adipolytic agent.

The aim of these trials is to evaluate the safety, tolerability and efficacy of ATX-101 in reducing submental fat levels compared to placebo, with around 720 patients set to be involved in the research.

It is hoped that the results of the phase III programme will support Intendis' plans to begin introducing the treatment to the commercial market from 2014 onwards.

Marc Lafeuille, president and chief executive officer of Intendis, said: "ATX-101 represents a promising product for Intendis to enter the growing aesthetic dermatology market."

This comes in the same week that Bayer HealthCare also announced the commencement of a new phase III trial for regorafenib, a treatment for gastrointestinal stromal tumours.ADNFCR-8000103-ID-800337067-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.